Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) are contraindicated due to mechanistic overlap with GLP-1 agonists
Tendon injuries, muscle tears, and ligament damage all reportedly respond more rapidly to combination protocols than to either peptide alone
Usage & Storage Description Retatrutide is a novel triple receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously
Rotating injection sites prevents lipodystrophy
The general guidelines are as follows: Administer the injection once a week, on the same day each week, at any time of day
Layne Norton: Gene, CRP or CRP
US$ 29.45
US$ 22.46
US$ 23.56
US$ 28.92
US$ 25.18
US$ 24.50
US$ 23.97
US$ 22.16
US$ 21.23
